



Innovating for
affordable healthcare

Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

Shilpa House # 12-6-214/A-1, Hyderabad Road,
RAICHUR - 584 135, Karnataka, India.

Phone : +91-8532-238704, Fax : +91-8532-238876

E-mail : info@vbsilpa.com Website : http://www.vbsilpa.com

CIN No. L85110KA1987PLC008739

Dated: 20 April, 2019

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.
Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

This is to inform you that the Company has received U.S Food and Drug Administration approval for its ANDA, Busulfan Injection, 60 mg/10 mL on 18.04.2019.

Busulfan Injection, 60 mg/10 mL is a generic equivalent of reference listed drug (RLD), Busulfex Injection, 60 mg/10 mL, used in the treatment of patients with chronic myelogenous leukemia as recommended in the label approved by FDA."

According to IQVIA MAT Q4 2018 data, the US market for Busulfan Injection, 60 mg/10 mL is approximately US\$ 32.8 Million.

This is for your information and doing the needful.

With Regards,

For **SHILPA MEDICARE LIMITED**


SUSHIL BAJAJ
CHIEF FINANCIAL OFFICER

